Skip Navigation


Hum. Reprod. Advance Access originally published online on May 12, 2005
Human Reproduction 2005 20(7):1798-1804; doi:10.1093/humrep/deh830
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
20/7/1798    most recent
deh830v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Pirard, C.
Right arrow Articles by Loumaye, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pirard, C.
Right arrow Articles by Loumaye, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions{at}oupjournals.org

GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin*

C. Pirard, J. Donnez1 and E. Loumaye

Department of Gynecology, Cliniques Universitaires St Luc, Université Catholique de Louvain, B-1200 Brussels, Belgium

1 To whom correspondence should be addressed at: Department of Gynecology, Cliniques Universitaires St Luc, Université Catholique de Louvain, B-1200 Brussels, Belgium. Email: donnez{at}gyne.ucl.ac.be

BACKGROUND: The study objective was to investigate whether repeated intranasal administration of a GnRH agonist could provide convenient and safe luteal support. METHODS: Twenty-four patients with unexplained infertility were enrolled. All patients were treated with an aromatase inhibitor. When ovulation trigger criteria were met, patients were randomly allocated to either 5000 IU hCG (group A), or 200 µg intranasal buserelin followed by 100 µg every 3 days (group B), 100 µg every 2 days (group C), or 100 µg every day (group D), up to day 14 of the luteal phase. All patients underwent intrauterine insemination. RESULTS: Follicular development was similar in all groups with 1.1 ± 0.3 follicles ≥16 mm, 229.4 ± 95.2 pg/ml estradiol (E2) and 0.8 ± 0.5 ng/ml progesterone (mean±SD). The luteal phase duration (median; 95% confidence interval) was 15 (14.1, 15.0), 14 (12.5, 15.5), 15 (11.8, 18.2) and 15 (14.4, 15.6) days in groups A, B, C and D respectively. From luteal phase day 7 onwards, progesterone levels tended to be higher in group D compared with A. On day 14 of the luteal phase, progesterone levels were 3.0 (0.8, 5.2), 1.7 (–0.5, 3.9), 3.9 (–0.7, 8.5) and 7.7 (3.4, 11.9) ng/ml in groups A, B, C and D respectively (P=0.045). No pregnancy was recorded in group A, but there was one biochemical pregnancy in group B, one biochemical and one singleton clinical pregnancy in group C, and two singleton clinical pregnancies in group D. CONCLUSION: Intranasal administration of buserelin could be effective to provide luteal support. This treatment was associated with a good pregnancy rate (5/18, 28%).

Key words: aromatase inhibitor/buserelin/GnRH agonist/intrauterine insemination/luteal support

*This research was presented in part at the European Society of Human Reproduction and Embryology 20th Annual Meeting, Berlin, Germany, June 2004.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
B. Ata, K. Yakin, B. Balaban, and B. Urman
GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonistprotocol: a randomized, controlled double blind study
Hum. Reprod., March 1, 2008; 23(3): 668 - 673.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
H.M. Fatemi, B. Popovic-Todorovic, E. Papanikolaou, P. Donoso, and P. Devroey
An update of luteal phase support in stimulated IVF cycles
Hum. Reprod. Update, November 1, 2007; 13(6): 581 - 590.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
C. B. Lambalk and R. Homburg
GnRH agonist for luteal support in IVF? Setting the balance between enthusiasm and caution
Hum. Reprod., October 1, 2006; 21(10): 2580 - 2582.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
J. Tesarik, A. Hazout, R. Mendoza-Tesarik, N. Mendoza, and C. Mendoza
Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles
Hum. Reprod., October 1, 2006; 21(10): 2572 - 2579.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
C. Pirard, J. Donnez, and E. Loumaye
GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study
Hum. Reprod., July 1, 2006; 21(7): 1894 - 1900.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser
The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization
Endocr. Rev., April 1, 2006; 27(2): 170 - 207.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.